SRR6013563
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.750
- INTERFERON_GAMMA_RESPONSE+0.680
- INFLAMMATORY_RESPONSE+0.560
- IL6_JAK_STAT3_SIGNALING+0.550
- ALLOGRAFT_REJECTION+0.530
- PROTEIN_SECRETION+0.510
- TNFA_SIGNALING_VIA_NFKB+0.510
- COMPLEMENT+0.500
- KRAS_SIGNALING_UP+0.460
- TGF_BETA_SIGNALING+0.440
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.260
- KRAS_SIGNALING_DN-0.240
- WNT_BETA_CATENIN_SIGNALING-0.230
- MYOGENESIS-0.150
- APICAL_JUNCTION-0.090
- MYC_TARGETS_V2-0.070
- APICAL_SURFACE-0.040
- CHOLESTEROL_HOMEOSTASIS-0.040
- ESTROGEN_RESPONSE_LATE-0.040
- DNA_REPAIR-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934811 | — | — | 0.911 |
| 2 | MNG1215 | — | — | 0.905 |
| 3 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.894 |
| 4 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.892 |
| 5 | BS_XF0ZX2B3 | EPN | Supratentorial EPN | 0.891 |
| 6 | f62519fa-7479-4e20-9ae4-d57f8a1e0e64 | — | — | 0.891 |
| 7 | SRR934924 | — | — | 0.889 |
| 8 | SRR12696731 | — | — | 0.888 |
| 9 | SRR934807 | — | — | 0.885 |
| 10 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.750 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.680 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.460 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| APOPTOSIS | 0.420 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |